24Dec2020

CEO STATEMENT 2020/2021

26Jun2020

ERC Belgium, has submitted to the EMA(European Medicines Agency) its Marketing Authorization Application (MAA) for conditional approval of its lead product Gliovac/ERC1671/SITOIGANAP to treat recurrent glioblastoma (GBM).
01May2020

ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency.
30Apr2020

12 Month Progress Report 30/04/2019-30/04/2020
24Apr2020

ERC Launches Development Program for Novel Cell-Based Therapeutic and Prophylactic SARS-CoV-2 Vaccine
20Apr2020

LATEST SITUATION – CEO STATEMENT
09Apr2020

ERC covid product launch against covid19
01Apr2020

In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA
23Mar2020

Do Academics kill more patients than the disease?
27Dec2019

Abigail-Alliance Humanitarian of the year award 2019

 In recognition of ERC’s commitment, Doctor Stathopoulos has received the Abigail-Alliance award for Humanitarian of the year 2019 for the ERC RTT program and Gliovac/ERC1671. Click...
27Feb2019

Decision of National organisation of Medicines of Greece

Issue: CU-10/JAN/2019
Approval of Temporary Individual Access to Early Access to the Medicinal Product GLIOVAC in Greece.
31Aug2018

12 month progress report 31/08/2017-31/09/2018

ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also know as ERC1671) toward commercialization.
08Jul2016

New production site in the Netherlands

ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671 against glioblastoma brain cancer, as well as vaccines based on the same,...
15May2016

Approval for open phase II study

ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination with Gliovac/ERC1671 vs standard treatments ...
29Mar2016

Interest to use our technology for other cancers

Based on the visibility of preliminary results for GBM, independent groups expressed their strong interest to use the technology for other cancers.